Дело C-859/24: Advanz Pharma/Комисия, Определение от 26 март 2025 г.

Текст

... sation – Application for suspension of operation of a measure – No urgency )

In Case C‑859/24 P(R),

APPEAL under the second paragraph of Article 57 of the Statute of the Court of Justice of the European Union, brought on 12 December 2024,

Advanz Pharma Ltd, established in Dublin (Ireland), represented initially by J. Bourgeois, avocat, and M. Meulenbelt, advocaat, and subsequently by B. Baum, Rechtsanwältin, O. Beghin, avocat, and M. Meulenbelt and A. Vermulst, advocaten,

appellant,

the other party to the proceedings being:

European Commission, represented by R. Lindenthal, E. Mathieu and A. Spina, acting as Agents,

defendant at first instance,

THE VICE-PRESIDENT OF THE COURT,

after hearing the Advocate General, M. Szpunar,

makes the following

Order

1. By its appeal, Advanz Pharma Ltd seeks to have set aside the order of the President of the General Court of the European Union of 26 November 2024, Advanz Pharma v Commission (T‑455/24 R, EU:T:2024:863; ‘the order under appeal’), by which he dismissed its application for interim measures, seeking an immediate and temporary suspension of operation of Commission Implementing Decision C(2024) 6281 final of 30 August 2024 revoking, under Article 20 of Regulation (EC) No 726/2004 of the European Parliament and of the Council, the conditional marketing authorisation, granted by Implementing Decision C(2016) 8685 final, for Ocaliva, an orphan medicinal product for human use (‘the decision at issue’).

Legal context

2. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to ...